Mesoblast Up 25% After Hours on Collaboration With Novartis
20 11월 2020 - 7:53AM
Dow Jones News
By Josh Beckerman
Mesoblast Ltd. American depositary receipts surged 25% to $14.70
after hours as the company entered an exclusive worldwide license
and collaboration agreement with Novartis AG for Mesoblast's
mesenchymal stromal cell product remestemcel-L.
The initial focus will be on treatment of acute respiratory
distress syndrome, including that associated with Covid-19.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 19, 2020 17:38 ET (22:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Mesoblast (ASX:MSB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Mesoblast (ASX:MSB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
